Updated Company Presentation and Shareholder Webinar
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
28 February 2025
Biome Australia’s Updated Company Presentation and Shareholder Webinar
Announcement
●
●
●
Biome Australia updates its Company Presentation
Biome Australia schedules webinar for Friday 7th March, 10.00am-10.45am AEDT
Webinar details and registration link to be shared in a separate announcement on Monday
3rd March
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the company’) is
pleased to invite investors to the company’s Investor Webinar on Friday 7th March 2025 from
10.00am-10.45am AEDT.
Hosted by Biome Australia Managing Director, Blair Vega Norfolk, the Investor Webinar will
explore the half yearly results. Full details of the webinar and link will be shared in a separate
announcement on Monday 3rd March 2025.
-ENDSApproved for release by the Biome Australia board of directors.
About Biome Australia Limited
Biome Australia develops, licenses, commercialises and markets innovative, evidence-based
live biotherapeutics (probiotics) and complementary medicines, many of which are supported
by clinical research. Biome aims to improve health outcomes and quality of life, and make its
products accessible to all.
Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with
some of the world's leading organisations in microbiome research and development, Biome
produced several unique live biotherapeutic (probiotic) products with innovative delivery
technologies that improve their stability and efficacy to create its flagship range of
complementary medicines: Activated Probiotics®.
Supported by clinical research, including randomised double-blind placebo-controlled trials,
Activated Probiotics help prevent and support the management of various health concerns,
including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS.
Through practitioner-only distribution, Biome is committed to educating health professionals
on the newfound systemic health effects of the gut microbiota, helping them to provide
innovative, evidence-based natural medicines for the management of some of humanity's
most prevalent and chronic health concerns.
For more information visit: www.biomeaustralia.com
Investor Relations
Lauren Caruana
+61 (3) 9017 5800
corporate@biomeaustralia.com
Media enquiries
media@activated.co
Biome Australia
March 2025
Jan 2024 Strategy Meeting
Company
Presentation
Blair Vega Norfolk, Founder & Managing Director
Company Presentation | March 2025
1
Biome Australia
Disclaimer
This presentation and the information contained within it (the
“information”) has been prepared solely for the use and benefit of the
person to whom it is provided (the “recipient”).
It has been provided to the recipient on a strictly confidential basis solely
for the purpose of assisting the recipient to determine whether it may be
interested in participating in the investment opportunity described in this
presentation (“Opportunity”) and if so, to participate in that process, and
may only be used for that purpose.
This presentation contains selected information only and does not
purport to contain all of the information that may be relevant to the
Opportunity.
The information is not a prospectus, disclosure document, product
disclosure statement or other offering document under Australian law or
under any other law. This presentation has not been filed, registered or
approved in any jurisdiction.
The information is provided for general information purposes only,
without taking into account any person’s objectives, financial situation or
needs.
It should not be relied on by the recipient in considering the merits of any
particular transaction, including the Opportunity. The recipient should
consider its own financial situation, objectives and needs and conduct its
own independent investigation and assessment of the contents of the
Information.
Past performance information included in this presentation is provided for
illustrative purposes only, should not be relied upon and is not an
indication of future performance.
Biome Australia Limited (“Company”) and its related bodies corporate,
directors, officers, partners, employees, advisers, consultants and agents
make no representation nor give any warranty, express or implied, as to
the accuracy, completeness, reliability, timeliness or suitability of the
information or that the information may be used in any given way or to
achieve any given result.
Company Presentation | March 2025
This presentation contains forward-looking statements, which may be
identified by words such as ʻmay’, ʻcould’, ʻbelieves’, ʻestimates’, ʻexpects’
or ʻintends’ and other similar words that connote risks and uncertainties.
Certain statements, beliefs, and opinions contained in this presentation, in
particular those regarding the possible or assumed future financial or
other performance, industry growth or other trend projections are
predictions only, and not guarantees, and subject to inherent risks and
uncertainties.
Except to the extent required by law, none of the Company, its Related
Persons or any other person gives any assurance that the results,
performance or achievements expressed or implied by the
forward-looking statements contained in this presentation will actually
occur and investors are cautioned not to place undue reliance on such
forward-looking statements.
A summary of the key risks associated with the Company, its business and
an investment in its shares is set out at the end of this presentation. All
forward-looking statements are subject to risk factors, many of which are
beyond the control of the Company and its Related Persons and, if they
were to occur, could cause the Company’s actual financial results to differ
materially from the results expressed or anticipated in the
forward-looking statements. The information should be read in
conjunction with the risk factors set out at the end of this presentation.
The recipient must, and agrees with the Company that it will, make its
own independent assessment of the accuracy, completeness, reliability,
timeliness and suitability of the information and its own determination of
whether the information is appropriate to be used for any given purpose.
The recipient will rely upon the information at its own risk.
To the maximum extent permitted by law, the Company and its Related
Persons exclude and disclaim all liability for any loss, damage, cost or
expense suffered by the recipient or any other person arising from or in
connection with use or reliance on (in any manner) the information or the
recipient’s participation in the Opportunity, whether the loss, damage,
cost or expense arise because of negligence, default, misrepresentation or
some other cause, and whether or not foreseeable. To the maximum
extent permitted by law, the recipient (on its own behalf and on behalf of
each of its representatives) unconditionally and irrevocably releases the
Company and its Related Persons from all claims and liability. The
Company holds this release for itself and on trust for its Related Persons.
The information contained in this presentation represents the
Company’s strategy as determined by the board of directors as at the
date of this presentation (15 November 2024), and the board reserves
its right to change this strategy and conduct the business of the
Company as appropriate having regard to changes in market or
operating conditions.
The information is based on an assessment of the economic and
operating conditions as at the date of this presentation, and on a number
of assumptions regarding future events and actions that, as at the date of
this presentation, are expected to take place. Except to the extent required
by law, the Company and its Related Parties will not be updating or
revising the information.
2
Biome Australia
About Biome
Australia
Biome Australia (ASX: BIO) is focused on becoming a
global leader in the complementary medicine industry,
offering clinically-proven, condition-specific probiotic
products fueled by novel clinical research programs to
cement and extend the evidence base of its probiotic
products.
Activated Probiotics, Biome’s flagship range of novel
live-biotherapeutics (probiotics), was created in
partnership with world leading organisations in
microbiome research and utilises innovative delivery
technologies that improves their stability and efficacy.
Biome has a B Corporation certification, a designation
that a business is meeting high standards of verified
performance, accountability and transparency.
Company Presentation | March 2025
3
Biome Australia Group
The Microbiome Health Company
Our mission
To prevent disease, improve health
outcomes and quality of life, and
make our products accessible to all
Company Presentation | March 2025
4
Biome Australia Group
Company Presentation | March 2025
The Microbiome Health Company
55
Biome Australia
02. Activated
Probiotics Range
Company Presentation | March 2025
2025
6
Biome Australia
Activated
Probiotics
Practitioners & Pharmacies
CONSUMER BENEFITS
5x more effective delivery — MicrobacTM technology
Shelf-stable
Clinically documented probiotic strains
Company Presentation | March 2025
7
Biome Australia
01. Business Highlights
Company Presentation | March
March2025
2025
8
Biome Australia
Biome Business
Highlights
Over 6,000 distribution points (Aus) following
successful launch with Priceline Pharmacy
Average shopper ~2.5 units per transaction and 6
visits per year in pharmacy (Terry White Scan data)
#1 growth Practitioner-Only brand in Australian Healthcare
Practitioner (HCP) Market (Retail scan sales and wholesaler data)
Activated Probiotics #1 growth brand in category in
TerryWhite and Priceline Pharmacy
Activated Probiotics #1 growth brand with Symbion, API
Wholesale and entire pharmacy market (VMS)
Successfully launched EU business and commenced
launch into North America via Canada
Company Presentation | March 2025
9
Biome Australia
Biome Business
Highlights
1H25 sales revenue of $8.9m (vs $13m FY24)
EBITDA $122k in Q1 & $230k in Q2, an increases of 89%
Net profit of $96,228 (excl R&D rebate) for H1 or $433,395(incl
R&D rebate)
Retail scan sales for two largest pharmacy groups average over
80% growth for 12 months to December 31 2024
61% gross margin
Sales revenue growth for FY24 total 80% and international
95%
Company Presentation | March 2025
10
Biome Australia
03. Distribution and Sales
Model
Company Presentation | March 2025
11
Biome Australia
Training and Education Driven
Sales Model - Practitioner Only
Unique Education and Service Model
Drives Sales in Australia, UK and NZ
Education and Service Support
Company Presentation | March 2025
•
The Biome sales team is a mix of health qualified practitioner education consultants and
territory managers
•
Practitioner education consultants undertake high level product detailing and training in
community pharmacy and with independent health practitioners
•
High quality training and education develops stronger trust and relationships with health
practitioners
•
Biomes support leads to active recommendations of Biome Australia products
•
Digital educational content and assets effectively support the national sales team in
servicing practitioner markets
•
Health Clinics are provided to key accounts to gain trust and develop existing accounts
12
Biome Australia
04. Vision 27
Company Presentation March
| March
2025
2025
13
Biome Australia
Vision 27
Revenue Growth
Biome has a three year cumulative sales revenue target of up to $85m. ($75m-$85m for
FY25-FY27)
●
This represents an increases of 350% on $24m for the three previous years
1. Distribution Growth & Business Development
●
●
●
Grow the existing 5000* (~40% TAM for distribution) Australian distribution points
(Pharmacy and Practitioner) to 8000 (~67% TAM for distribution)
○
6000 passed in January 2025
Business development in underdeveloped accounts
Co-prescribing / adjunct prescribing dispensary opportunity in developed accounts
(330m prescriptions or opportunities in pharmacy per year in 2024)
2. International Market Acceptance and Growth
●
Company Presentation | March 2025
Gain traction and brand recognition as well as meaningful sales volume in both
European and North American markets
○ Further European geographies are under review for future launches
○
North America (Canada) is set for test market launch in FY25 after Biome received
initial Health Canada approvals in Q4 FY24
○
Distribution deal signed with Ecotrend Ecologics (Canada)
14
Biome Australia
Vision 27
Bring Activated Probiotics to the mainstream market as a
significant probiotic brand locally and abroad.
3. Supply Chain
●
Identification and viability analysis of a novel probiotic strain that is
proprietary to Biome
○
○
●
Lactobacillus plantarum BMB18
○
Positive results on this project was shared with the market in
Jan 2025
○
FaBA finding support for IP development released on Feb 4
2025
Supporting new product development and further protection from
competition
Actively reviewing opportunities to optimise
production run and production timing
4. New Brand and Product Range
●
Company Presentation | March 2025
Activated Therapeutics and Product Range Launch in H2 FY25
○
Initial four new products will go straight into Biome’s
existing practitioner distribution network
15
Biome Australia
03. Distribution Growth &
Business Development
Company Presentation | March 2025
16
Biome Australia
Distribution Growth & Business
Development
●
Biome has grown its Australian distribution
from 100 distribution points in 2019 to 6000 in
2025 - the total addressable distribution market
for Biome in our local market is ~12,000.
●
Existing distribution (6000) is expected to be
~40% developed at the close of FY25. This
leaves significant potential for scale in both
number of accounts and average account
revenue through Vision 27 and beyond.
Company Presentation | March 2025
17
Biome Australia
03. IP
Development
Company Presentation | March 2025
18
Biome Australia
BMB18
Biome has executed an agreement to develop a Biome owned novel
probiotic strain
●
Lactobacillus plantarum BMB18
Biome has successfully completed the identification, commercial
validation and initial characterisation of the probiotic strain Lactobacillus
plantarum BMB18
The strain has been lodged with the German culture bank DSMZ
Biome has received positive results of core functional characterisation
studies of its strain BMB18
The strain demonstrated an ability to effectively modulate immune
responses and inflammation, reduce oxidative stress, and maintain
intestinal barrier integrity
This new IP will strengthen Biome’s advantage in probiotic product
development and increase protection from competition
Long term asset, once developed will add material value to Biome’s
balance sheet
Company Presentation | March 2025
19
Biome Australia
05. International
Markets
Company Presentation | March 2025
2025
20
Biome Australia
Canada — North America
International markets grow 95% to reach ~$895k in sales
revenue for FY24
Company Presentation | March 2025
●
Health Canada Approvals received in H2 FY24 (12/17
Activated Probiotics products)
●
Test market launch successful with Ecotrend In Q1 FY25
●
First territory manager hired in Ontario (Toronto) in
November 2024
●
Move to official market launch from November 2024
21
Biome Australia
06. New Product
Development
Company Presentation | March 2025
22
Biome Australia Group
Company Presentation | March 2025
The Microbiome Health Company
23
Biome Australia
Summary
●
FY24 Sales Revenue $13.01m, up 80%
●
Q2 FY25 Sales Revenue $4.6m (new record)
●
●
●
Q2 $229,917 EBITDA adjusted for non-cash, share-based payments)
●
1H FY25 $351,765 EBITDA (adjusted for non-cash, share-based payments)
●
●
●
Gross Margin at 61%
●
$2.6m cash balance at December 31 2024
●
Over 6,000 distribution points (Australia)
●
EU market launched and Canadian market launch underway
●
●
Company Presentation | March 2025
FY25 Q1 pharmacy same stores sales up 68% (vs
PCP)
Three ongoing clinical trials on key products
Average shopper ~2 units per transaction and 6
visits per year in pharmacy (Terry White CM)
Activated Probiotics #1 growth brand
in TerryWhite and Priceline Pharmacy
Activated Probiotics #1 growth with Symbion & API
Delivering $50,000+ per sqm gross margin return
on floor space in key accounts
24
Biome Australia
Contact details
Blair Norfolk, CEO
Douglas Loh, CFO
Email
corporate@biomeaustralia.com
Websites
biomeaustralia.com
activatedprobiotics.com.au
Company Presentation | March 2025
25
Share your feedback
Discover